CN102107032B - External medicine feeding device applied in macromolecular drug of low-molecular substance in blood and application thereof - Google Patents
External medicine feeding device applied in macromolecular drug of low-molecular substance in blood and application thereof Download PDFInfo
- Publication number
- CN102107032B CN102107032B CN200910251060.XA CN200910251060A CN102107032B CN 102107032 B CN102107032 B CN 102107032B CN 200910251060 A CN200910251060 A CN 200910251060A CN 102107032 B CN102107032 B CN 102107032B
- Authority
- CN
- China
- Prior art keywords
- blood
- molecular substance
- molecular
- macromolecular drug
- reaction chamber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- External Artificial Organs (AREA)
Abstract
The invention discloses an external medicine feeding device applied in macromolecular drug of low-molecular substance in blood and application thereof, wherein a blood purifier comprises a shell; the shell is provided with a reaction cavity and a blood passage which are isolated by a semipermeable membrane with intercepting molecular weight not less than 3000 Dalton of substance; an inlet and an outlet are arranged in the blood passage; the reaction cavity is filled with drugs for affecting the low-molecular substance needing being reduced or removed in blood; a blood circulation pipeline system comprises an input pipeline communicated with the inlet of the blood passage and an output pipeline communicated with the outlet of the blood passage; and a blood conveying bump is arranged on the input pipeline. The device provided by the invention can solve the problem that the medical zymoprotein and other macromolecular drugs needing reducing or removing the low-molecular substance in blood are difficult to feed; the device can be used continuously, and other low-molecular substances needed by human body in blood are not removed; as the macromolecular drug and cell are isolated from the plasma protein, the side effect is little; the volume of the device is small; and the production and use cost of the device is reduced.
Description
Technical field
The present invention relates to a kind of apparatus for purifying blood, particularly a kind of treated in vitro device of the macromolecular drug that acts on lower-molecular substance in blood.
Background technology
In human body, molecular weight is less than 3000Dalton, can be diffused into blood and also can be called lower-molecular substance by the material of conventional semipermeable membrane by cell membrane.
Specific lower-molecular substance in human body needs reduced by selectivity or remove sometimes, with treatment relevant disease or prevent the generation of the relevant diseases such as liver declines, renal failure, metabolic disease, specific tumor, particularly mainly contain following four kinds of situations: (1) inherited genetic factors causes specific metabolic pathway disappearance to make to be changed the specific endogenous lower-molecular substance of even being drained by metabolism and accumulates, and causes histoorgan infringement or individual growth dysplasia or abnormal; (2) human liver or renal function obstacle due to various Pathophysiologys, makes body planted agent be accumulated by the specific endogenous lower-molecular substance of metabolism or excretion, causes the infringement of histoorgan or the dysplasia of individuality or abnormal; (3) a variety of causes causes special exogenous lower-molecular substance to accumulate in vivo, and causes infringement or the individual growth dysplasia or abnormal of histoorgan; (4) under normal physiological level, in blood, the supply of special lower-molecular substance is the prerequisite that pathological tissues pathological changes worsens, and reduces grade malignancy that the level of these lower-molecular substances in blood plasma is conducive to reduce pathological tissues even when blocking lesion evolution.
In prior art, reduce or remove special lower-molecular substance in blood mainly containing following two kinds of methods:
The first is physical method, utilizes the macromole such as the large and protein of the volume of cell can not see through the character such as semipermeable membrane, collect the lower-molecular substance in blood and exchange by body fluid by dialysis to excrete, thus these lower-molecular substances in minimizing blood.Equipment therefor is mainly Acute renal failure equipment, and this is the main Types of the auxiliary back-up system of many organs such as current artificial liver or artificial kidney.Existing Continuous renal replacement therapy conventionally by the pipeline of UNICOM's blood and drug delivery pump system, blood purification filter, the body fluid of collecting lower-molecular substance by disperse or convection current supplements with three basic function module such as balance sysmte and forms, the functional separation that sometimes also cell separation can be separated with plasma protein is arranged to two parts to promote the removing of pathogenic protein involved in blood, as the removing of proinflammatory cytokine etc., thereby improve the effect for the treatment of by blood purification; Conventionally these devices all need meticulous electronic monitoring and control system to detect blood pressure and to leak blood.The defect of this method is there is no selectivity, and a lot of lower-molecular substances of needed by human body all can synchronously be removed or reduce.Therefore, this class apparatus for purifying blood all must comprise body fluid volume balance and the body fluid components replenishment system that precision is very high, make that device is very complicated and cost is very high, in replacement process, body fluid consumption is very large, equipment cannot be carried, and is mainly used in clinical Intensive Care Therapy therapeutic room (ICU) or has body fluid replacing the concentrated place of supply system.
The second is chemical method, mainly comprise following two kinds of subclass: (1) first subclass uses lower-molecular substance as medicine, this class medicine and needing reduces or the low-molecular material qualitative response removed be converted into nonhazardous or low molecular product that human body can tolerate or be transformed into for the lower-molecular substance that promotes enzyme catalysis in body to transform to make to be reduced or to remove that nonhazardous or human body can tolerate even the low molecular product to human body beneficial products as complementary substrate or for activating the specific enzymes protein and other in body.The representative of this class low-molecule drug be treatment heavy metal ion poisoning 1,3-dimercaptopropanol, BAL, promote pralidoxime, the reduced glutathion that promotes the non-nutritious matter metabolism such as bilirubin etc. that inactivation acetylcholine esterase brings back to life.The major defect of these medicines is that selectivity is not high, effect limited even when dosage is larger side effect larger.This class drug main will be by intravenous injection or oral administration at present.(2) second subclass use pheron macromole as medicine, utilize the special catalytic action of pheron corresponding lower-molecular substance selectivity is reduced or remove, this fermentoid protein drug is main by intravenous injection or other rational method administration at present, and this class pheron mainly in blood, by catalytic reaction, the lower-molecular substance of need removing is optionally transformed into nonhazardous or human body can tolerate even useful to human body low molecular product.The representative of this fermentoid protein macromolecule medicine is after the phenylalanine hydroxylase of uricase, the asparaginase for the treatment of some tumor and arginine desimidase, the treatment phenylketonuria for the treatment of hyperuricemia relevant disease (as gout), the acetylcholine esterase of removing cocaine in blood or cocaine esterase, organophosphate poisoning, to remove the acetylcholine esterase of organophosphorus pesticide or to oxygen esterase etc.This fermentoid protein macromolecule medicine for reducing or to remove the main advantage of specific lower-molecular substance in blood be that selectivity is high, substantially do not affect the level of other lower-molecular substance in body, as long as the appropriate effect for the treatment of of consumption can meet the demands.The major defect of this fermentoid protein macromolecule medicine is that it depends on intravenous administration mostly, its preparation needs very high purity and cost is very high, the quality of the pharmaceutical preparations requires very high and technical difficulty is very large, more trouble is that most these class pherons belong to foreign protein or itself are not exposed to the protein of immune surveillance system, there is immunogenicity in vivo and easily removed by immune system, cause that its circulating half-life is very short, dosage is very large and strengthened cost, and immunogenicity also easily causes corresponding toxic and side effects.Can eliminate the macromolecular immunogenicity of most of medicinal pheron by hydrophilic polymer-modified such as Polyethylene Glycol (PEG), but this causes medicine cost higher, preparation process is more complicated, and the specific activity of polyethyleneglycol modified rear medicinal pheron all can decline.For in blood plasma because this lower fermentoid protein macromolecule medicine of reason specific activity such as optimum pH deviation is larger, as uricase or arginine desimidase, its consumption is larger.When the current treatment of the uricase intravenous administration with high PEG degree of modification gout (each 10mg left and right, monthly once), people knows from experience the anti-PEG antibody of generation, and this is very unfavorable to treating diseases such as needing the gout of continuous use.Therefore, in minimizing or removing body inner blood, the route of administration of the medicinal pheron of special lower-molecular substance is current insoluble technical problem.In theory, also has the third subclass, with hydrophilic polymer macromole with the low-molecular material qualitative response that needs in blood to be reduced or to be eliminated to eliminate the unfavorable physiological action of these lower-molecular substances, but this class macromole is seldom used at present, and preparation requirement is identical with pheron class macromole, cost is very high.
Therefore, need a kind of apparatus for purifying blood and method, can solve an administration difficult problem that reduces or remove the macromolecular drugs such as the required medicinal pheron of lower-molecular substance in blood, there is selectivity and seriality, and the lower-molecular substance that can not remove needed by human body in blood, can not produce toxic and side effects in use procedure, device volume is little, use flexibly, reduce making and the use cost of device.
Summary of the invention
In view of this, object of the present invention provides a kind of treated in vitro device and application thereof of the macromolecular drug that acts on lower-molecular substance in blood, can solve an administration difficult problem that reduces or remove the macromolecular drugs such as the required medicinal pheron of lower-molecular substance in blood, there is selectivity and seriality, and the lower-molecular substance that can not remove needed by human body in blood, can not produce toxic and side effects in use procedure, device volume is little, use flexibly, can significantly reduce making and the use cost of device.
The treated in vitro device of the macromolecular drug that acts on lower-molecular substance in blood of the present invention, comprises blood purification and blood circulation conduit system;
Described blood purification comprises housing, arrange in described housing by molecular cut off and be more than or equal to reaction chamber and the blood channel that the semipermeable membrane of 3000Dalton material separates, described blood channel arranges import and outlet, the in-built macromolecular drug that is reduced or removes lower-molecular substance effect with blood domestic demand that is useful on of reaction chamber, the molecular weight of the macromolecular drug in described reaction chamber is greater than the molecular cut off of semipermeable membrane.
Described blood circulation conduit system comprises the input channel being communicated with blood channel import and exports with blood channel the output channel being communicated with, blood transport pump is set on described input channel.
Further, in described housing, form row tubular structure by semipermeable membrane pipe, tube side is blood channel, and shell side is reaction chamber;
Further, waste liquid outlet is set described reaction chamber and body fluid supplements mouth, and described waste liquid outlet and body fluid supplement mouth stop valve is set respectively; Waste liquid outlet and body fluid supplement between mouth and reaction chamber and all separate by described semipermeable membrane;
Further, described semipermeable membrane molecular cut off is greater than the material of 5000Dalton;
Further, described semipermeable membrane is hollow fiber type polysulfone membrane;
Further, described housing arranges closed opening;
Further, described doser also arranges blood pressure and leaks blood monitoring system.
The invention also discloses a kind of application of treated in vitro device of the macromolecular drug that acts on lower-molecular substance in blood, comprise the following steps:
A. determine and need the lower-molecular substance kind that is reduced or removes in blood, and according to in blood, need to be reduced or to remove lower-molecular substance effect need in the reaction chamber of doser, pack corresponding macromolecular drug into;
B. starting blood transport pump makes blood pass through blood channel, in blood, lower-molecular substance sees through semipermeable membrane and enters reaction chamber, macromolecular drug in lower-molecular substance and the reaction chamber that need be reduced or remove is had an effect and is changed, make to need in reaction chamber the lower-molecular substance that is reduced or removes to keep lower level, in blood channel inner blood, need the lower-molecular substance that is reduced or removes to continue to diffuse to reaction chamber by semipermeable membrane; This process circulation continuous meets the requirements to needing to be reduced or remove lower-molecular substance content in blood;
C. according to whether existing other need be reduced or remove lower-molecular substance in blood, change the interior medicine of reaction chamber and repeat b step.
Further, macromolecular drug used can be pheron or complex catalyst and lower-molecular substance that optionally catalysis need be reduced or remove be transformed into nonhazardous or human body can tolerate the low molecular product to human body beneficial products even or for complementary substrate for the lower-molecular substance that promotes enzyme catalysis in reaction chamber to transform to make to be reduced or to remove be transformed into can not see through the macromole product of semipermeable membrane or for macromolecule polyalcohol can directly generate with the low-molecular material qualitative response that carrys out autoblood can not be through the macromole product of semipermeable membrane.
Beneficial effect of the present invention: the treated in vitro device of the medicine that acts on lower-molecular substance in blood of the present invention, the structure that adopts macromolecular drug to combine with semipermeable membrane, collect the low molecular composition of easily diffusion in reaction chamber, in reaction chamber, add the macromolecular substances of special single or multiple pherons or the cross-linking agent of these pherons (can spread or non-dispersive substrate as needs also can add) or direct and lower-molecular substance effect, the low molecular composition that directly in reaction chamber, need is reduced or is removed carries out enzyme catalysis conversion, or directly add the macromolecular drug that is reduced or removes low-molecular material qualitative response with need, thereby optionally these lower-molecular substances are transformed into the low molecular composition that nonhazardous or human body can tolerate, even can not see through again the component of polymer of semipermeable membrane, or utilize these need be reduced or remove low molecule to transform the low molecular composition that simultaneously provides useful to human body, react by the catalytic action of enzyme or with macromolecular drug, cause these need be reduced or remove lower-molecular substance higher concentration difference inside and outside blood purification filter, utilize this larger concentration difference to accelerate needing the selectivity that is reduced or removes lower-molecular substance reduce or remove in blood, conventionally unaltered other low molecular composition and nonhazardous and the useful low molecular product of human body all can be seen through semipermeable membrane and finally be covered to blood in enzymic catalytic reaction or direct reaction mixture.
For the continuous blood purification mode of pure physics, this device is reduced or is removed the special lower-molecular substance in blood by enzyme catalysis or other macromolecular drug effect selectivity, can not rely on physical absorption and removes lower-molecular substance; Significantly reduce body fluid magnitude of recruitment and reduced the requirement to body fluid balance Control system resolution, can omit body fluid balance control system and realize the miniaturization of equipment and portability is used, to maintain the very low level of the specific lower-molecular substance of blood, be particularly suitable for the treatment of chronic disease for macromolecular drug administration; For the intravenous administration of chemical method macromolecular drug used, medicine used carry out autoblood but there is no cell and the reaction chamber of blood protein in play a role and directly do not enter blood, avoid medicine contacting and interaction with cell in blood and protease, thereby avoid the immunoreation of human body and can eliminate the immunity rejection effect to pharmaceutical protein, made medication safer; Meanwhile, substantially without the impact on macromolecular drug stability from cell or plasma proteinase, the dosage of macromolecular drug can be more greatly to ensure therapeutic effect, be conducive to maintain in blood specific lower-molecular substance in lower level; The doser of this macromolecular drug plays a role macromolecular drug in vitro, control to the macromolecular drug quality of the pharmaceutical preparations is easier, gross standard is without diffusible toxic low molecular composition, preparation cost is significantly reduced, be particularly useful for the inhuman source pheron class drug administration of recombinant expressed manufacture and production.
Brief description of the drawings
Below in conjunction with drawings and Examples, the invention will be further described.
Accompanying drawing is structural representation of the present invention.
Detailed description of the invention
Accompanying drawing is structural representation of the present invention, as shown in the figure: the treated in vitro device of the macromolecular drug that acts on lower-molecular substance in blood of the present embodiment, comprises blood purification and blood circulation conduit system;
Described blood purification comprises housing 1, arrange in described housing by molecular cut off and be more than or equal to reaction chamber 2 and the blood channel 3 that the semipermeable membrane of 3000Dalton separates, described blood channel 3 arranges import 31 and outlet 32, the in-built macromolecular drug that is useful on the lower-molecular substance effect that is reduced or removes with blood domestic demand of reaction chamber 2, the macromolecular drug molecular weight in described reaction chamber 2 is greater than the molecular cut off of semipermeable membrane; To guarantee that it is difficult to see through semipermeable membrane and strengthen its heat stability, to improve its heat stability prolong half-life.
The macromolecular drug that is reduced or removes lower-molecular substance effect with blood domestic demand refers to that the lower-molecular substance direct reaction that can optionally reduce with need or remove generates the macromolecular substances of macromole product, or can catalysis need be reduced or remove lower-molecular substance and be transformed into the pheron of low molecular product that nonhazardous or human body can tolerate or the low molecular product to human body beneficial products, can realize goal of the invention.
Described blood circulation conduit system comprises the input channel 4 being communicated with blood channel 3 imports 31 and exports 32 output channels that are communicated with 5 with blood channel 3, on described input channel 4, blood transport pump 6 is set; In practice, input channel 4 also arranges anticoagulant and adds entrance 9, adds anticoagulant in case Hemostatic Oral Liquid solidifies; If human body direct purification blood, is communicated with blood thereby input channel and output channel can finally be connected to conventional single-tube double-cavity remaining needle.
The present invention can be made into small/micro device, can carry for maintaining blood and need to be reduced or to remove the low-level of lower-molecular substance, the blood channel in pipeline (with delivery pump), the blood purification filter of its need connection blood and the reaction chamber of collection lower-molecular substance; Macromolecular drug adds or injects through closed opening and adds in reaction chamber, and the need that this device mainly depends in the catalytic action of pheron or the minimizing of the direct reaction of macromolecular drug or removing blood are reduced or remove lower-molecular substance; And can intermittent iron supplement macromolecular drug, realize long-term maintenance treatment object; Can not need body fluid replacement process.
In the present embodiment, in described housing 1, form row tubular structure by semipermeable membrane pipe, row tubular structure refers to multiple semipermeable membrane pipes and is set up in parallel, and layout can be regular, can be also irregular, does not affect the realization of the object of the invention; Tube side is blood channel 3, and tube side refers in pipe; Shell side is reaction chamber 2, and shell side refers to the shell intracorporeal space being positioned at outside pipe; This structure has larger diffusion area, can improve the diffusion velocity of lower-molecular substance, thereby improves the efficiency that low molecule reduces or removes.
In the present embodiment, waste liquid outlet 7 is set described reaction chamber 2 and body fluid supplements mouth 8, described waste liquid outlet 7 and body fluid supplement mouth 8 stop valve (being respectively stop valve 71 and stop valve 81 in figure) are set respectively, waste liquid outlet and body fluid supplement between mouth and reaction chamber and all separate by described semipermeable membrane, and isolation retains macromolecular drug; Open valve and can remove fast specific lower-molecular substance in blood by the displacement of body fluid, be applicable to the treatment that toxic lower-molecular substance that acute poisoning or internal organs grievous injury cause excessively accumulates corresponding disease; In the present embodiment, can directly add or inject macromolecular drug is joined in reaction chamber 2, open corresponding stop valve, reduce fast need corresponding in blood by the body fluid displacement of use in conjunction blood purification and the effect of macromolecular drug and be reduced or remove lower-molecular substance, accelerate minimizing or the removing of these toxic lower-molecular substances in blood purification process; Reach after certain level, close stop valve, normally use this device; By macromolecular drug, the special lower-molecular substance in blood purification filter is transformed into (low molecule or macromole) product that nonhazardous or human body can tolerate and is even transformed into the low molecular product useful to human body, low molecular product can spread covering in body; Can reduce the concentration of corresponding lower-molecular substance in reaction chamber by the effect of macromolecular drug, promote that in blood, corresponding lower-molecular substance enters in reaction chamber, under limited body fluid exchange capacity, produce more potent fruit.
In the present embodiment, the molecular cut off of described semipermeable membrane is greater than the material of 5000Dalton; Can stop the macromole such as protein, can improve the diffusion velocity of lower-molecular substance, increase work efficiency.
In the present embodiment, described semipermeable membrane is hollow fiber type polysulfone membrane.
In the present embodiment, described housing 1 arranges closed opening 10, and for adding medicine and taking out reactant liquor, closed opening 10 can be to add a cover, and can be also directly at opening part plug rubber stopper, and self-closed after injectable drug is easy to use.
Described doser also arranges blood pressure and leaks blood monitoring system, and described blood pressure and leakage blood monitoring system are conventional electronic monitoring and control system (not representing in figure)
The present invention acts on the application of the treated in vitro device of the macromolecular drug of lower-molecular substance in blood, comprises the following steps:
A. determine that low molecule need be reduced or remove substance classes in blood, and according to in blood, need to be reduced or to remove lower-molecular substance effect need in the reaction chamber of doser 2, pack corresponding macromolecular drug into, can adopt injection or directly add the mode of sealing again to add macromolecular drug by opening 10, macromolecular drug used can be that pheron or complex catalyst and lower-molecular substance that optionally catalysis need be reduced or remove are transformed into nonhazardous or human body can tolerate the even low molecular product to human body beneficial products, or for complementary substrate is for promoting the enzyme catalysis conversion in reaction chamber to make the lower-molecular substance that need be reduced or remove be transformed into the macromole product that can not see through semipermeable membrane, or generate the macromole product that can not see through semipermeable membrane for macromolecule polyalcohol energy is direct with the low-molecular material qualitative response that carrys out autoblood,
B. by blood transport pump 6 by the blood transport of need processing to blood channel 3, simultaneously according to circumstances add blood anticoagulant, as shown in the figure, anticoagulant adds by adding entrance 9; In blood, lower-molecular substance enters reaction chamber through the blood channel of semipermeable membrane, lower-molecular substance and the macromolecular drug that need be reduced or remove be had an effect, and need the lower-molecular substance that is reduced or removes to continue to diffuse to reaction chamber by semipermeable membrane in blood channel inner blood; Being circulated to needs to be reduced or removes lower-molecular substance content in blood and meet the requirements; Product can tolerate or useful to human body as nonhazardous or human body, and reactant mixture can all cover in body, can not use body fluid balance and replenishment system; Or generate under enzyme effect with the complementary macromolecule substrate that can not spread can not diffuse into blood channel product again physical removal also can omit body fluid balance and replenishment system; If consumed the macromolecular drug of non-pheron in reaction chamber, need gap to supplement this macromolecular drug to maintain the continuous firing of this device;
C. according to whether existing other need be reduced or remove lower-molecular substance in blood, change the interior macromolecular drug of reaction chamber and repeat b step; So that the effect that continues performance minimizing or remove lower-molecular substance in blood.
Device of the present invention and application have following features:
(1) this device when administration the macromolecular drug such as pheron directly do not enter blood but play a role in the reaction chamber of isolating with blood, therefore pheron plays a role outward at blood when this device is used for medicinal pheron administration, belong to treated in vitro, required pheron preparation is equivalent to external application preparation.
(2) as long as ensureing molecular cut off, semipermeable membrane just can be used for making the blood purification filter of this macromolecular drug treated in vitro device at macromole such as the above protein of 5000Dalton.
(3) the special lower-molecular substance in blood purification filter is transformed into (low molecule or macromole) product that nonhazardous or human body can tolerate and is even transformed into the low molecular product useful to human body, low molecular product can spread covering in body; Can reduce the concentration of corresponding lower-molecular substance in blood purification filter by enzyme catalysis, promote that in blood, corresponding lower-molecular substance enters in blood purification filter, under limited body fluid exchange capacity, produce more potent fruit.
(4) product can tolerate or useful to human body as nonhazardous or human body, and reactant mixture can all cover in body, and body fluid balance and replenishment system can be omitted; Or generate under enzyme effect with the complementary substrate that can not spread can not diffuse out blood purification filter product again physical removal also can omit body fluid balance and replenishment system.
Finally explanation is, above embodiment is only unrestricted in order to technical scheme of the present invention to be described, although the present invention is had been described in detail with reference to preferred embodiment, those of ordinary skill in the art is to be understood that, can modify or be equal to replacement technical scheme of the present invention, and not departing from aim and the scope of technical solution of the present invention, it all should be encompassed in the middle of claim scope of the present invention.
Claims (5)
1. a treated in vitro device that acts on the macromolecular drug of lower-molecular substance in blood, is characterized in that:
Comprise blood purification and blood circulation conduit system;
Described blood purification comprises housing, arrange in described housing by molecular cut off and be more than or equal to reaction chamber and the blood channel that the semipermeable membrane of 3000Dalton material separates, described blood channel arranges import and outlet, the in-built macromolecular drug that is reduced or removes lower-molecular substance effect with blood domestic demand that is useful on of reaction chamber, the molecular weight of the macromolecular drug in described reaction chamber is greater than the molecular cut off of semipermeable membrane;
Described blood circulation conduit system comprises the input channel being communicated with blood channel import and exports with blood channel the output channel being communicated with, blood transport pump is set on described input channel;
In described housing, form row tubular structure by semipermeable membrane pipe, tube side is blood channel, and shell side is reaction chamber;
Waste liquid outlet is set described reaction chamber and body fluid supplements mouth, and described waste liquid outlet and body fluid supplement mouth stop valve is set respectively; Waste liquid outlet and body fluid supplement between mouth and reaction chamber and all separate by described semipermeable membrane.
2. the treated in vitro device of the macromolecular drug that acts on lower-molecular substance in blood according to claim 1, is characterized in that: described semipermeable membrane molecular cut off is greater than the material of 5000Dalton.
3. the treated in vitro device of the macromolecular drug that acts on lower-molecular substance in blood according to claim 2, is characterized in that: described semipermeable membrane is hollow fiber type polysulfone membrane.
4. the treated in vitro device of the macromolecular drug that acts on lower-molecular substance in blood according to claim 3, is characterized in that: described housing arranges closed opening.
5. according to the treated in vitro device of the macromolecular drug that acts on lower-molecular substance in blood described in the arbitrary claim of claim 1 to 4, it is characterized in that: described doser also arranges blood pressure and leaks blood monitoring system.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910251060.XA CN102107032B (en) | 2009-12-29 | 2009-12-29 | External medicine feeding device applied in macromolecular drug of low-molecular substance in blood and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910251060.XA CN102107032B (en) | 2009-12-29 | 2009-12-29 | External medicine feeding device applied in macromolecular drug of low-molecular substance in blood and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102107032A CN102107032A (en) | 2011-06-29 |
| CN102107032B true CN102107032B (en) | 2014-08-27 |
Family
ID=44171386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910251060.XA Expired - Fee Related CN102107032B (en) | 2009-12-29 | 2009-12-29 | External medicine feeding device applied in macromolecular drug of low-molecular substance in blood and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102107032B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115739032B (en) * | 2022-08-30 | 2024-05-28 | 江苏恰瑞生物科技有限公司 | Preparation method of graphene filler of blood perfusion device for decomposing arginine |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1511596A (en) * | 2002-12-26 | 2004-07-14 | ������������ʽ���� | Dialyser and its producing method |
| CN1761494A (en) * | 2003-03-17 | 2006-04-19 | 甘布罗伦迪亚股份公司 | Blood treatment device and method with selective solute extraction |
| CN1879900A (en) * | 2005-06-17 | 2006-12-20 | 缪志俊 | In vitro molecular adsorption and circulation system |
| CN201033178Y (en) * | 2007-04-05 | 2008-03-12 | 苏州大学附属第一医院 | Novel external artificial liver supporting and treating system |
| CN101298041A (en) * | 2008-06-24 | 2008-11-05 | 天津德欧特生物医药科技有限公司 | Adsorbing agent for blood perfusion adsorbing bilirubin in vitro and preparation |
| CN101610799A (en) * | 2007-02-15 | 2009-12-23 | 旭化成可乐丽医疗株式会社 | Blood purification system |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE532147C2 (en) * | 2005-02-16 | 2009-11-03 | Triomed Ab | Portable dialysis system |
-
2009
- 2009-12-29 CN CN200910251060.XA patent/CN102107032B/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1511596A (en) * | 2002-12-26 | 2004-07-14 | ������������ʽ���� | Dialyser and its producing method |
| CN1761494A (en) * | 2003-03-17 | 2006-04-19 | 甘布罗伦迪亚股份公司 | Blood treatment device and method with selective solute extraction |
| CN1879900A (en) * | 2005-06-17 | 2006-12-20 | 缪志俊 | In vitro molecular adsorption and circulation system |
| CN101610799A (en) * | 2007-02-15 | 2009-12-23 | 旭化成可乐丽医疗株式会社 | Blood purification system |
| CN201033178Y (en) * | 2007-04-05 | 2008-03-12 | 苏州大学附属第一医院 | Novel external artificial liver supporting and treating system |
| CN101298041A (en) * | 2008-06-24 | 2008-11-05 | 天津德欧特生物医药科技有限公司 | Adsorbing agent for blood perfusion adsorbing bilirubin in vitro and preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102107032A (en) | 2011-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20050083627A (en) | Selective plasma exchange therapy | |
| KR20090023747A (en) | Bicarbonate-based solutions for dialysis therapies | |
| WO1996009876A1 (en) | Artificial liver apparatus and method | |
| CN108430529A (en) | system and method for extracorporeal blood treatment | |
| TW201034708A (en) | Dialysis machine, a manifold for the dialysis machine and process | |
| CN104958795A (en) | Whole blood perfusion bioartificial liver system | |
| GB1601223A (en) | Method and apparatus for continuous ambulatory peritoneal dialysis | |
| CN106075625A (en) | A kind of Biotype artificial liver | |
| CN102107032B (en) | External medicine feeding device applied in macromolecular drug of low-molecular substance in blood and application thereof | |
| CN103040740A (en) | Ornidazole injection and preparation technology thereof | |
| US9511053B2 (en) | Nitric oxide scavengers | |
| CN205515729U (en) | Blood purifying device and system | |
| CN113509606A (en) | Device for reducing uric acid in body | |
| CN112604051B (en) | Total-liver type bioartificial liver system | |
| CN115992045A (en) | Cell processing apparatus and cell processing method | |
| CN204766767U (en) | Whole blood perfusion bioartificial liver system | |
| CN211561296U (en) | Double-chamber blood filter | |
| Tanveer et al. | Assessment of the risk factors and various patient related attributes influencing hemodialysis | |
| CN200951242Y (en) | Disposable sterile filtering type intravenous injection syringe | |
| CN103463094B (en) | Medicine composition of cefpiramide sodium and infant compound amino acid injection (19AA-I) | |
| CN214859943U (en) | Multifunctional transfusion system | |
| CN221845637U (en) | Pairing plasma dialysis replacement device | |
| CN113769189B (en) | Non-isolated insulin controlled-release drug entrapment equipment and entrapment method | |
| RU204435U1 (en) | Biocomposite filter for the biological circuit of the extracorporeal hemoperfusion system | |
| CN220158878U (en) | Continuous blood purifying pipeline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140827 Termination date: 20191229 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |